Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation

Biliary tract cancer (BTC) comprises a group of rare and anatomically distinct epithelial cell tumours of the biliary tree, including gallbladder carcinoma (GBC), intrahepatic cholangiocarcinoma (IHC) and extrahepatic cholangiocarcinoma (EHC), which together account for approximately 1% of adult cancers worldwide [1]. Despite being rare, BTCs are an important cause of cancer-related mortality and display a dismal prognosis, even with sequential chemotherapy. Geographically, the incidence of GBC is highest in Southeast Asia, Latin America and Eastern Europe and demonstrates a female preponderance [2,3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research